How can therapeutic peptide development be accelerated? 

That is really the question we have been trying to answer as we have built our peptide division. Our customers tell us that one of the major issues they face is the lost time in moving between suppliers from early stage research to clinical development and again into commercial supply. Every change and transfer adds delay and risk. 

Biosynth have set out to build a real first-in-class peptide development and manufacturing platform, where we can work with our customers from discovery, toxicology, clinical studies, and out to ongoing commercial supply and fill-finish of peptide drug product.  

Following our acquisition of Pepceuticals last year (Biosynth adds Multi-Kilogram GMP Peptide synthesis | News | Biosynth), industry news experts The Medicine Maker found out more about how we are addressing this gap in the market and about how Pepceuticals really were a “hidden gem”. 

Find out more about our GMP peptide offering or Contact us to discuss your needs